LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

PCR-RFLP Distinguishes Between Co-Endemic New World Leishmania Species

By LabMedica International staff writers
Posted on 08 Sep 2014
Image: Map of Mexico with Leishmania endemic regions studied shown in maroon coloring – from left to right the states: Veracruz, Tabasco, Campeche, and Quintana Roo (Photo courtesy of Prof. Monroy-Ostria A. et al., the Instituto Politecnico Nacional, and the journal Interdisciplinary Perspectives on Infectious Diseases).
Image: Map of Mexico with Leishmania endemic regions studied shown in maroon coloring – from left to right the states: Veracruz, Tabasco, Campeche, and Quintana Roo (Photo courtesy of Prof. Monroy-Ostria A. et al., the Instituto Politecnico Nacional, and the journal Interdisciplinary Perspectives on Infectious Diseases).
In a study of clinical samples from patients in southeast Mexico, a PCR-RFLP assay was effective in differentiating between co-endemic species of Leishmania—enabling more fine-tuned diagnoses and more appropriate treatments for patients in a given population with different forms of American (New World) leishmaniasis.

American cutaneous leishmaniasis (CL) includes: localized CL (LCL) caused by L. (L.) mexicana; diffuse CL (DCL) caused by L. (L.) amazonensis, Leishmania (L.) venezuelensis, and Leishmania (L.) pifanoi; and mucosal CL (MCL) caused by members of the L. braziliensis complex. In endemic regions, multiple species of Leishmania may coexist. Identification of the infecting species based on clinical symptoms is difficult, especially since several species can cause both LCL and MCL. Diagnostic confirmation and correct identification are important for appropriate species-specific therapeutics as well as epidemiologic studies.

In an international collaboration led by Amalia Monroy-Ostria, professor at the Escuela Nacional de Ciencias Biológicas of the Instituto Politecnico Nacional (IPN; Mexico City, Mexico), a PCR-RFLP (restriction fragment length polymorphism) assay based on the conserved ITS1 (internal transcribed spacer 1) genes was evaluated for direct diagnosis of leishmaniasis and identification of parasite species that, to small but significant extent, coexist in Leishmania-endemic regions of southeast Mexico. Most clinical samples examined, 109/116 (94%), gave patterns similar to L. mexicana, 2 gave patterns similar to L. braziliensis, and 5 gave patterns that suggest a co-infection of 2 strains: co-infection of L. (L.) mexicana and L. (V.) braziliensis or of L. (L.) mexicana and L. (L.) amazonensis. Of 21 Leishmania isolates, 52% displayed a pattern similar to the L. (L.) mexicana strain, 5% showed a mixed pattern compatible with L. (L.) mexicana and L. (V.) braziliensis, 8 with L. (L.) amazonensis and L. (L.) mexicana, and 1 to L. (V.) braziliensis.

The ITS1 PCR-RFLP assay enables diagnosis of leishmaniasis directly (without need for parasite isolation from clinical samples) and simultaneous determination of most infecting species of New World Leishmania, in relatively short time and low cost. Improvements can be made, for example, by further tailoring to sequences that may be found to more specifically characterize local Leishmania species for a given region (e.g., with respect to gene sequences amplified in the PCR or to restriction enzymes used for the RFLP).

The study, by Monroy-Ostria A. et al., was published in the journal Interdisciplinary Perspectives on Infectious Diseases, July 2014.

Related Links:

Instituto Politecnico Nacional


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more